- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Zenas BioPharma files to sell 6.31M shares of common stock for holders | 3 | Seeking Alpha | ||
| 10.10. | Hedge Fund and Insider Trading News: Jeffrey Ubben, Ken Griffin, Chris Hohn, Bill Ackman, Scott Bessent, Alden Global Capital, Balyasny Asset Management, Eisler Capital, Zenas Biopharma Inc (ZBIO), Dell Technologies Inc (DELL), and More | 13 | Insider Monkey | ||
| 10.10. | Fierce Pharma Asia-TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment | 2 | FiercePharma | ||
| 09.10. | Zenas BioPharma rises after Wedbush raises price target | 4 | Seeking Alpha | ||
| 09.10. | H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion | 2 | Investing.com | ||
| 09.10. | China's InnoCare Plunges After Granting Overseas Rights for Three Innovative Drugs to US Peer Zenas | 1 | Yicai Global | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.10. | Zenas BioPharma files automatic mixed securities shelf | 1 | Seeking Alpha | ||
| 08.10. | Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug | 1 | Benzinga.com | ||
| 08.10. | Zenas looks to China to stock pipeline with 3 more immune drugs | 2 | BioPharma Dive | ||
| 08.10. | Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare | 2 | FiercePharma | ||
| 08.10. | Zenas climbs on licensing deal with InnoCare | 2 | Seeking Alpha | ||
| 08.10. | Zenas Biopharma stock soars after securing rights to MS drug candidate | 1 | Investing.com | ||
| 08.10. | Zenas Biopharma licenses three autoimmune candidates from InnoCare | 1 | Investing.com | ||
| 08.10. | Zenas BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.10. | INNOCARE, Zenas Forge Global Strategic Co-op & License Deal with Total Potential Value USD2B+ | 2 | AASTOCKS | ||
| 08.10. | Zenas und InnoCare schließen Lizenzvertrag für MS-Medikament im Wert von 2 Mrd. US-Dollar | 3 | Investing.com Deutsch | ||
| 08.10. | Zenas, InnoCare ink $2 billion MS drug licensing deal | 1 | Investing.com | ||
| 08.10. | Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis | 84 | GlobeNewswire (Europe) | - Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple... ► Artikel lesen | |
| 02.09. | Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line | 3 | FierceBiotech | ||
| 02.09. | Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab | 432 | AFX News | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 254,95 | -0,06 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 505,80 | +0,36 % | Regeneron Says CHMP Recommends Libtayo For EU Approval As Adjuvant Treatment Of CSCC | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,340 | +0,78 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 32,540 | +0,34 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
| INSMED | 139,00 | 0,00 % | UBS reiterates Buy rating on Insmed stock, sees upside for Brinsupri | ||
| SWEDISH ORPHAN BIOVITRUM | 29,980 | +3,59 % | Swedish Orphan Biovitrum AB: Change in the Sobi Board of Directors | STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned... ► Artikel lesen | |
| SCHOLAR ROCK | 25,200 | +2,44 % | Truist Securities senkt Kursziel für Scholar Rock wegen Verzögerung bei Markteinführung | ||
| PROQR THERAPEUTICS | 2,360 | +0,51 % | ProQR Therapeutics N.V.: ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 | ||
| CRINETICS PHARMACEUTICALS | 34,400 | -1,71 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 06.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.10.2025.ISIN NameAT0000A3PGY9 UBM... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 3,860 | 0,00 % | Ventyx stock soars after positive Phase 2 results for inflammation drug | ||
| ENSYSCE BIOSCIENCES | 2,050 | 0,00 % | Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 | ~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 38,850 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis | LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases... ► Artikel lesen | |
| TEVOGEN BIO | 0,514 | -10,14 % | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,500 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,660 (-6,38 %) liegt der Kurs bei 24,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.